Efficacy of Doll Therapy in the Control of Behavioral and psychologIcal Symptoms of Dementia in Acute Geriatric Inpatients: the AGITATE Study.

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Summary. Behavioral and psychological symptoms of dementia (BPSD) represents a huge emotional stress and an important burden for the patients and the caregivers severely reducing their quality of life. BPSD worsen during hospitalization and require the administration of psychotropic drugs that are often insufficient to control the symptoms, and may cause severe adverse events. The investigators propose the use of empathy dolls in order to reduce BPSD and in particular agitation and aggressiveness in acute geriatric in-patients affected by moderate to severe forms of dementia. The use of doll therapy in the clinical routine will allow to reduce the use of psychotropic drugs, shorten hospitalization, reduce professional and family caregiver burden improving patients' and families' quality of life.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:

• age ≥65 years

• diagnosis of dementia moderate to severe Clinical Dementia Rating scale (CDR) ≥2

• presence of agitation and/or aggressiveness

• manual and visual abilities sufficient in order to interact with the doll.

Locations
Other Locations
Switzerland
geriatric and Geriatric Rehabilitation Unit
RECRUITING
Lausanne
Contact Information
Primary
Patrizia D Amelio, MD, PhD
patrizia.damelio@chuv.ch
+41213143712
Time Frame
Start Date: 2024-11-15
Estimated Completion Date: 2027-08-30
Participants
Target number of participants: 92
Treatments
Experimental: doll therapy
The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy
Other: non anthropomorphic object
non- anthropomorphic soft object
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire Vaudois

This content was sourced from clinicaltrials.gov